Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange Nov 26, 2021 08:30AM
Numinus Announces Departure of Stacey Wallin Nov 25, 2021 06:00PM
Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021 Nov 22, 2021 08:30AM
Numinus to Begin Trading on the OTC Under Symbol NUMIF Nov 19, 2021 08:30AM
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials Nov 10, 2021 05:00AM


Oct 26, 2021 09:00AM Numinus to Participate in Microdose Hosted Events: Psychedelic Capital and Wonderland: Miami
Oct 20, 2021 09:00AM Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Oct 8, 2021 09:00AM Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Sep 23, 2021 09:00AM Numinus Completes Acquisition of Neurology Centre of Toronto
Sep 2, 2021 09:00AM Numinus to Participate in Upcoming Investor Conferences in September 2021
Jul 29, 2021 06:00PM Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology
Jul 12, 2021 08:00AM Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Jun 24, 2021 07:45PM Numinus Announces Grant of Stock Options
Jun 18, 2021 08:00AM Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
Dec 2, 2020 08:00AM Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
Oct 14, 2020 08:30AM Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council
Sep 24, 2020 08:30AM Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory